Elite Pharmaceuticals, Inc.
ELTP
$0.53
$0.010.95%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 224.16% | -1,055.62% | 411.07% | -1,641.89% | -173.90% |
| Total Depreciation and Amortization | -7.66% | -9.02% | 3.93% | 39.69% | 66.27% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | -- | -- | -- |
| Total Other Non-Cash Items | -137.01% | 837.05% | -5.31% | 241.73% | 211.33% |
| Change in Net Operating Assets | -70.68% | -654.28% | -511.75% | 62.80% | 17.83% |
| Cash from Operations | 250.38% | 369.89% | 86.62% | 55.47% | 717.55% |
| Capital Expenditure | -11.80% | 71.97% | -86.84% | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -686.93% | 86.88% | -86.84% | 100.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 16.90% | -2,261.75% | 61.02% | -413.56% | -78.66% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 63.67% | -2,261.75% | 65.84% | -413.56% | -78.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 323.38% | 698.21% | 133.76% | 55.63% | 377.73% |